HomeBUSINESS
BUSINESS

Fuji Pharma Might Review Development Plans for Nesp Biosimilar Expecting Fierce Competition
(Nov.24.2017)

Fuji Pharma President Eiji Takemasa
Fuji Pharma might review its plan to develop a biosimilar of the renal anemia treatment Nesp (darbepoetin alfa), which it is currently developing in Japan, President Eiji Takemasa suggested at a business briefing on November 21. He noted that other companies aim to launch biosimilars and an authorized biosimilar version of Nesp, making this “a product that will face fierce competition.” ...
(LOG IN FOR FULL STORY)